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Abstract
Background: Clausena excavata Burm.f. is a shrub traditionally used to treat cancer patients in Asia. The main
bioactive chemical components of the plant are alkaloids and coumarins. In this study, we isolated clausenidin from
the roots of C. excavata to determine its apoptotic effect on the colon cancer (HT-29) cell line.
Method: We examined the effect of clausenidin on cell viability, ROS generation, DNA fragmentation, mitochondrial
membrane potential in HT-29 cells. Ultrastructural analysis was conducted for morphological evidence of apoptosis
in the treated HT-29 cells. In addition, we also evaluated the effect of clausenidin treatment on the expression of
caspase 3 and 9 genes and proteins in HT-29 cells.
Result: Clausenidin induced a G0/G1 cell cycle arrest in HT-29 cells with significant (p < 0.05) dose-dependent
increase in apoptotic cell population. The DNA fragmentation assay also showed apoptotic features in the
clausenidin-treated HT-29 cells. Clausenidin treatment had caused significant (p < 0.05) increases in the expression
of caspase 9 protein and gene in HT-29 cells and mitochondrial ROS and mitochondrial membrane depolarization.
The results suggest the involvement of the mitochondria in the caspase-dependent apoptosis in clausenidin-treated
colon cancer cells.
Conclusion: Clausenidin induces a caspase-dependent apoptosis in colon cancers through the stimulation of the
mitochondria. The study demonstrates the potential of clausenidin for use in the treatment of colon cancers.
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Background
Colon cancer is the second leading cause of cancer
deaths worldwide accounting for over 1.4 million new
cases each year [1, 2]. Colon cancers are rising at an
alarming rate in countries where very few treatment op-
tions are available. It is projected that from 2015 to 2030
the incidence of the disease in developing countries will
increase by as much as 60 % [3] and will present great
challenges to the management of the cancer. It has been
shown that there are close associations between molecu-
lar signaling, energy generation, and proliferation of tu-
mors [4, 5]. Since these molecular mechanisms can
promote tumor cell proliferation, they are usually the
targets of cancer chemotherapies [6].
Cancer chemotherapeutic agents are screened and se-
lected based on their potentials to induce apoptosis [7].
Apoptosis is an integral cell death program characterized
by DNA fragmentation as well as loss of mitochondrial
membrane integrity [8]. This mode of cell death is
driven by caspases and proceeds via the extrinsic or in-
trinsic pathways. The intrinsic pathway of apoptosis is
tightly coordinated by the mitochondria via the activa-
tion of caspase 9 [9, 10]. Because of the integral role it
plays, caspase 9 is often referred to as gatekeeper of the
mitochondrial pathway [11]. Upon activation, caspase 9
activates caspase 3, whose action leads to the execution
of apoptosis. Apoptotic strategies to destroy tumor cells
may involve direct stimulation of pro-apoptotic mole-
cules, modulation of anti-apoptotic proteins or induction
of tumor suppressor function [12]. The functions of
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caspase 9 gene and promoter help to drive apoptosis to
ensure that abnormal and senescent cells are removed
from the body [13]. A comparison between the normal
and tumor cells of colorectal cancer patients had shown
decreased expression of caspase 9 in tumors [14]. In sit-
uations where tumors arise due to altered gene expres-
sion, treatments can be targeted towards improving the
expression of the gene because the activation or inhib-
ition of certain genes could stimulate apoptosis and alter
the kinetics of tumor growth [15].
Clausenidin (Fig. 1) is a natural pyranocoumarin from
Clausenidin excavata Burm. f., a wild shrub of the Ruta-
ceae family predominantly used in Asian folk medicine
[16, 17]. The plant has been used locally to treat cold, der-
matopathy, snake bite, malaria, HIV and abdominal pains
[18, 19]. In Thailand, it has been reported that Clausena
excavata is traditionally used in the treatment of cancers
[17]. In a recent study, Su et al. [20] isolated four pyrano-
coumarins from C. excavata and screened their cytotoxic
potentials in cancer cells. The study revealed that the pyr-
anocoumarins are good modulators of tumor cell death.
In another study dentatin isolated from C. excavata was
shown to increase the expression of caspase 9 in MCF-7
cells [21]. In our laboratory we observed that the ex-
pression of caspase 9 increases in clausenidin-treated
hepG2 cells (Unpublished report). However, the
underlying mechanisms by which clausenidin induces
apoptosis has not been fully resolved. The current
study describes for the first time, some molecular
mechanisms involved in clausenidin-induced cell
death in a colon cancer cell line. The study also pro-
vides insights on caspase-dependent apoptosis trig-
gered by clausenidin in colon cancers.
Methods
Extraction and isolation of compound
Fresh roots of Clausena excavata Burm.f. were collected
from the Agricultural Park, Institute of Bioscience,
University Putra Malaysia. The identification of the plant
material was done by Dr Shamsul Khamis of the Insti-
tute and a voucher specimen was deposited in the herb-
arium (2991/16). The roots (2 kg) were air-dried for
2 weeks, ground to fine powder and used for the extrac-
tion process. The extraction of clausenidin was per-
formed by soaking the fine powder in 1 L chloroform
for 3 days followed by filtration through 0.45 μm filter
paper (Sigma Aldrich, US) to collect the extract. The ex-
tract was subjected to glass column chromatography
through silica gel, as described by Arbab et al. [21], to
obtain pure clausenidin crystals (524 mg). The clau-
senidin crystals were subjected to mass spectrometry
(Shidmadzu GCMS-QP5050A) while the melting point
was determined using a Barnstead melting point appar-
atus [16, 18].
Cell viability assay
Human colon cancer (HT-29) cells were obtained from
American Type Culture Collection (ATCC, Va, USA)
and doxorubicin from EMD Millipore, US. The cells
were maintained in DMEM medium supplemented with
10 % Fetal Bovine Serum (FBS). About 5000 cells were
seeded into each well of a 96 well plate and incubated
for 24 h. Treatment was done with increasing concentra-
tions of clausenidin and doxorubicin (positive control).
Negative control cells were treated with 0.1 % (v/v)
DMSO. After 72 h, MTT (5 mg/mL) was added for the
viability assay as described previously by Syam [22]. Re-
sults obtained were expressed as percentage cytotoxicity
after 72 h exposure to test agents.
Morphological assessment of apoptotic cells by acridine
orange (AO) and propidium iodide (PI) double staining
Clausenidin induced cell death in HT-29 cells was moni-
tored using acridine orange (AO) and propidium iodide
(PI) double-staining according to standard procedures.
Cells were seeded in a 6 well plate (105cells/well) and in-
cubated overnight. The cells were treated for 24 h with
increasing concentrations of clausenidin after which the
cells were harvested and washed with PBS. The cells
were centrifuged at 1000 g for 5 min and the super-
natant was discarded. The washing procedure was re-
peated twice to remove traces of media from the cells.
Ten microliters (10 μl) of fluorescent dyes containing
AO (10 mg/mL and PI (10 mg/mL) were added into the
cellular pellet at equal volumes. Freshly stained cell sus-
pension was dropped on a glass slide and covered with a
cover slip. Slides were observed under fluorescent
microscope within 30 min before the fluorescence fades.
Transmission electron microscopy
To prepare the cells for transmission electron microscopy
(TEM), HT-29 cells were seeded at a density of 106cells/T-
Fig. 1 Structure of Clausenidin
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25 ml flask and incubated overnight. The cells were then
treated with the IC50 of clausenidin (13.8 μg/mL) in a time
dependent manner while the negative control cells were
treated with 0.1 % (v/v) DMSO. After treatment, cells were
harvested and washed with PBS before successive fixing
with 4 % glutaraldehyde for 24 h and 1 % osmium tetraox-
ide at 4 °C for 2 h. After each fixing, washing was done
three times with 0.1 M sodium cacodylate buffer. Dehydra-
tion of the cells was carried out with increasing concentra-
tions of acetone (30 – 99.9 %). Further processing of cut
sections was done using the method described by Tan et al.
[23]. The sections were stained with uranyl acetate and
viewed under the Hitachi H-7100 electron microscope.
ROS assay
The ROS assay was performed to measure the intra-
cellular ROS production from the mitochondria of
clausenidin-treated HT-29 cells. Briefly, cells were
seeded at a density of 2 × 105 cells/well in a 6 well
plate and incubated overnight. The cells were then
treated with clausenidin (13.8 μg/mL) at increasing
time period and harvested for the ROS assay, which
was performed using the Total ROS assay kit
(ebioscience Inc, Affymetrix) according to manufac-
turer’s protocol. The assay results were analyzed on a
flow cytometer (BD FACS, Calibur).
DNA fragmentation analysis
The HT-29 cells were seeded at a density of 106cells/ml
in culture flask and incubated overnight. The cells were
then treated with clausenidin (13.8 μg/mL) for 12 h and
24 h respectively after which the cells were harvested
and DNA was extracted using the suicide-track™ DNA
Ladder Isolation kit (Calbiochem, USA) according to the
manufacturer’s protocol. The principle involves detec-
tion of the cytoplasmic histone-associated DNA frag-
ments (mononucleosome and oligo- nucleosomes)
formed during apoptosis. After extraction, the concen-
tration and purity of the DNA was confirmed on a nano-
drop spectrophotometer. The extracted DNA samples
were run on a 1.5 % agarose gel in Tris–acetic acid–
EDTA buffer and gel image was captured on GelDoc
(Biorad, USA). HL-60 cells induced to undergo apoptosis
with Actinomycin D, supplied with the assay kit was
used as positive control.
Cell cycle analysis by flow cytometry
The HT29 cells were seeded at a concentration of
106cells/T-25 ml flask in RPMI media and incubated
overnight. The cells were then treated with clausenidin
(13.8 μg/mL) at an increasing time period while the
negative control cells were treated with 0.1 % (v/v)
DMSO. After treatment, cells were harvested and
washed with PBS. The cell cycle assay was performed
using BD cell cycle reagent (CycleTest™ Plus DNA re-
agent kit, Becton Dickinson, Belgium) according to man-
ufacturer’s protocol and the result was analyzed on a
flow cytometer (BD FACS, Calibur) using the BD cell
quest pro software.
Annexin V assay
HT-29 cells were seeded at a concentration of 2 ×
105cells/T-25 flask in RPMI media and incubated over-
night. The cells were then treated with increasing concen-
trations of clausenidin while the negative control was
treated with 0.1 % (v/v) DMSO. Cells were harvested after
treatment and washed with PBS. Annexin V assay was
then carried out using FITC annexin V assay kit (BD Phar-
mingen, USA) following the manufacturer’s protocol and
the result was analyzed on a flow cytometer.
Mitochondrial membrane potential (MMP) assay
Mitochondrial membrane potential assay was performed
to determine the polarization/depolarization of the mito-
chondrial membrane using the JC-1 dye. HT29 cells
were seeded at a density of 5 × 105cells/well in a 6 well
plate, incubated overnight and then treated with increas-
ing concentrations of clausenidin for a period of 24 h.
The negative control cells were treated with 0.1 % (v/v)
DMSO. The assay was performed using the BD™
Mitoscreen kit (BDbiosciences, US) according to man-
ufacturer’s instruction. The results were analyzed on a
flow cytometer (BD FACS, Calibur) using the BD cell
quest pro software.
Caspases 3 and 9 assays
Caspases 3 and 9 activity were determined using the col-
orimetric method (Genescript Colorimetric Assay kit,
USA). Cells were initially seeded in a 6 well plate at a
density of 106 cells/well overnight. The cells were treated
for 24 h with increasing concentrations of clausenidin
and then cleaved Caspases 3 and 9 assays were per-
formed respectively according manufacturer’s protocol.
Negative control cells were treated with 0.1 % (v/v)
DMSO. After the completion of reaction, the plates were
read on microplate reader at 405 nm.
RNA isolation
RNA extraction was basically done to study the expression
of the genes and get possible insights into the mechanism
of apoptosis induced by clausenidin. After treatment of
cells with clausenidin and 0.1 % DMSO (for negative con-
trol) in a 6 well plate (106cells/well), the cells were har-
vested with trypsin and washed with PBS. The RNA was
extracted using the Total RNA extraction kit (GF-1 TRE
kit, Vivantis technologies) according to the manufacturer’s
protocol. The extracted RNA was quantified using a nano-
drop spectrophotometer at 260 nm.
Waziri et al. BMC Complementary and Alternative Medicine  (2016) 16:256 Page 3 of 12
RT-qPCR
The reverse transcriptase quantitative PCR (RT-qPCR)
was carried out according to the GenomeLab GeXP Kit
(Beckman Coulter, USA) protocol, in an XP Thermal
Cycler (Bioer Technology, Germany). PCR products
were finally analyzed on the GeXP genetic analysis sys-
tem and the results normalized on express Profiler soft-
ware based on the manufacturer’s instructions. The
primers for the genes of interest and housekeeping gene
(Table 1) were designed on NCBI website and purchased
from Biosune (Shanghai, China), while the internal con-
trol (Kanr) was supplied by Beckman Coulter (USA).
Statistical analysis
Data were presented as mean ± standard deviation. One
way Analysis of Variance (ANOVA) on SPSS 22 software
(SPSS Inc, Chicago IL, USA) was used to assess the level
of significance between means at 95 % confidence inter-
val (p < 0.05).
Results
Cell viability and cytotoxicity assay
The cell viability assay was performed to evaluate the
percentage (%) cytotoxicity and IC50 of pure clausenidin
in HT-29 cells. Clausenidin induced cytotoxic effects in
HT-29 cells in a dose dependent manner (Fig. 2). The
IC50 of clausenidin obtained after treating the cells for
72 h is 13.8 ± 2.89 μg/mL while that of doxorubicin is
6.2 ± 0.14 μg/mL.
Fluorescent microscopy
The fluorescent microscopy was performed after staining
the clausenidin-treated cells with equal proportions of
acridine orange and propidium iodide dyes. The fluores-
cent micrograph reveals the apoptosis inducing effects
of clausenidin in HT-29 cells (Fig. 3). Some of the mor-
phological aberrations observed includes membrane
blebbing and chromatin condensation which are early
signs of apoptosis (Figs. 3b - d). In addition some cells
were observed to be undergoing secondary necrosis.
Transmission electron microscopy
To further confirm the occurrence of apoptosis, the ul-
trastructural micrograph of clausenidin treated HT-29
cells were monitored in a time dependent manner and it
revealed the presence of nuclei shrinkage and fragmenta-
tion, chromatin condensation, lipid droplets and convo-
lution of nuclei outline which are hallmarks of apoptosis
(Fig. 4). An increase in vacuolation and loss of microvilli
was observed as the treatment time increased.
ROS production assay
The production of ROS in HT-29 cells was measured
using flow cytometry in the FITC channel. The assay
method employed identified only cells that are actively
producing the intracellular ROS. The result in Fig. 5
shows that the percentage (%) of HT-29 cells producing
ROS increased significantly (p < 0.05) after treatment
with clausenidin at 24 h compared to the untreated cells.
However, a decline was observed at 48 and 72 h com-
pared to that of 24 h because the active ROS producing
Table 1 Gene name and sequences of primers used in the multiplex panel




Cyt c AGGTGACACTATAGAATAGAGCGAGTTTGGTTGC GTACGACTCACTATAGGGAAAATCTTCTTGCCTTTCTC
Caspase 3 AGGTGACACTATAGAATATGTAGAAGAGTTTCGTGAGT GTACGACTCACTATAGGGAGAGTTTTCAGTGTTCTCCAT
Caspase 9 AGGTGACACTATAGAATAGCTGGTGGAAGAGCTG GTACGACTCACTATAGGGACTCTAAGCAGGAGATGAACA
β-actin AGGTGACACTATAGAATAGATCATTGCTCCTCCTGAGC GTACGACTCACTATAGGGAAAAGCCATGCCAATCTCATC
The β-actin gene was used for normalization. Reverse transcription (RT) and PCR were done according to manufacturer’s instructions; RT reaction was at 480 °C for
1 min; 370 °C for 5 min; 420 °C for 60 min; 950 °C for 5 min; then held at 40 °C, while PCR was as follows: initial denaturation at 950 °C for 10 min, followed by
two-step cycles of 940 °C for 30 s and 550 °C for 30 s, ending in a single extension cycle of 680 °C for 1 min. Bax: Bcl-2-associated X protein; Bcl-2: B cell lymphoma
2; Apaf-1: Apoptotic protease activating factor 1; Cyt c: cytochrome complex; Caspase 3: Cysteine aspartic acid protease 3; Caspase 9: Cysteine aspartic acid
protease 9
Fig. 2 Cytotoxicity of HT-29 cells treated with clausenidin and
doxorubicin. The IC50 of clausenidin and doxorubicin is 13.80 ± 2.89
and 6.20 ± 0.14 μg/mL, respectively
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cells were dying due to the oxidative stress (Fig. 5c and
d). Conversely, the percentage of the non-active ROS
producing cells in the treatments decreased significantly
(p < 0.05) as the treatment time progressed. This is due
to stimulating effect of clausenidin which caused the
more cells to begin the production of ROS.
DNA fragmentation analysis
The HT-29 cells were treated with clausenidin (13.8 μg/mL)
at 12 h and 24 h which led to the generation of DNA frag-
ments shown in the gel image (Fig. 6). The untreated cells
(negative control) had their genomic DNA intact with no
fragments generated (lane C) unlike the treatments (lanes
A & B) and positive control (lane D). Clausenidin induced
an internucleosomal cleavage of DNA in HT-29 cells lead-
ing to the generation of fragments which is a basic feature
of apoptosis [24, 25].
Cell cycle analysis
The DNA content histograms of HT-29 cells treated
with clausenidin is shown in Fig. 7 which suggests a G0/
G1 phase arrest. The percentage cell distribution (Fig. 7e)
further reveals that clausenidin induces a G0/G1 phase
arrest in HT-29 cells. The percentage of apoptotic cells
(sub G0/G1) increased significantly (p < 0.05) compared
to the control as treatment time progressed to 72 h
(Fig. 7e) as a result of the cytotoxic effects of
clausenidin.
Annexin V Assay
The occurrence of apoptosis was further corroborated
using the annexin V and PI staining assay because
annexin V is able to bind membrane phospholipid which
is released prior to the loss of membrane integrity. The
annexin V assay distinguished between HT-29 cells in
early and late apoptotic state after exposure to clauseni-
din (Fig. 8). Overall, the result in Fig. 8 shows a signifi-
cant increase (p < 0.05) in the percentage of apoptotic
cells resulting from clausenidin treatment in a time
dependent manner compared to the untreated cells.
MMP Assay
The MMP assay was done to assess the mitochondrial
function, since it is an organelle that is intimately in-
volved in reception of signals that culminates in apop-
tosis. The MMP results shows a significant increase (p <
0.05) in collapse of MMP (green fluorescence) while a
concomitant significant decrease (p < 0.05) was observed
in the percentage of live cells with intact mitochondria
(red fluorescence) (Fig. 9). The green fluorescence is as a
result of increasing membrane depolarization while red
fluorescence is a reflection of high membrane
polarization after staining with the JC-1 dye.
Caspases 3 & 9
Caspase 9 is an initiator caspase whose function enables
the activation of executioner caspases such as caspase 3

















Fig. 3 Acridine orange and propidium iodide-stained clausenidin-treated HT-29 cells. b, c, d are treatments with 5, 15, and 30 μg/mL clausenidin,
respectively and (a) is the untreated control. VC - Viable cells, AP - apoptosis, MB - membrane blebbing, SN - necrosis. Analyses in triplicates.
*Significant difference between means at p < 0.05
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significant increase (p < 0.05) in the expression of cas-
pases 3 and 9 in HT-29 cells in a dose dependent
manner.
Gene expression studies
The gene expression studies was conducted to gain pos-
sible insights on how clausenidin affects the expression
of caspases genes and other apoptotic genes associated
with the mitochondrial pathway of apoptosis. The results
shows that clausenidin significantly increases (p < 0.05)
the expression of caspases 3 and 9 genes at 12 and 24 h
of treatment (Fig. 11). Similarly, the expressions of Cyt
c, Apaf-1, and Bax were significantly increased after 24 h
Fig. 5 Reactive oxygen species production by clausenidin-treated
HT-29 cells. Analyses in triplicates. *Significant difference between




Fig. 6 DNA fragmentation in clausenidin-treated HT-29 cells. A and
B are treatments (13.8 μg/mL) for 12 h and 24 h respectively, D is
positive control supplied with the kit while C is the untreated





















Fig. 4 Ultrastructural assessment of clausenidin-treated HT-29cells. b, c, d are treatments (13.8 μg/mL) for 24 h, 48 h, and 72 h respectively and
(a) is the untreated control. VA - vacuole; LD - lipid droplet; FN - fragmented nucleus; CC - chromatin condensation; CN - convolution of nuclear
outline. Analyses in triplicates
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Fig. 7 Cell cycle of clausenidin-treated HT-29 cells. b, c, d are DNA contents of cell treated for 24, 48, 72 h, respectively and (a) is untreated
control cells. e represents % cell count at cell cycle phases. Analyses in triplicates. (*Significant difference between means at p < 0.05)
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Fig. 8 Annexin V assay of clausenidin-treated HT-29 cells. b, c, d represent viable and dead cells after treatment for 24, 48, 72 h, respectively and
(a) is untreated control cells. e represents % cell count. Analyses in triplicates. (*Significant difference between means at p < 0.05)
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Fig. 9 Mitochondrial membrane potential assay of clausenidin-treated HT-29cells. b, c, d represent treatment with 5, 15, and 30 μg/mL clausenidin
respectively and (a) is the untreated control. Red fluorescence: cells with intact mitochondria, green fluorescence: cells with depolarized mitochondrial
membrane. e represents proportion of live and apoptotic cells. Analyses in triplicates. (*Significant difference between means at p < 0.05)
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of treatment with clausenidin compared to the untreated
cells.
Discussion
There are few literatures on the isolation of clausenidin
and its potential cytotoxic effects but none of the reports
have clearly defined the mechanism of action of clause-
nidin in any cancer cell line. In this particular study, we
investigated the cascade of reactions that triggers
apoptosis in HT-29 cells treated with clausenidin from
Clausena excavata. It was observed that apoptosis oc-
curred in the clausenidin treated HT29 cells via caspase
9 mediated signaling.
The purified clausenidin induced cytotoxic effects in
HT-29 cells in a dose dependent manner with an IC50 of
13.8 ± 2.89 μg/mL. This could be a justification for the
wide usage of C excavata in Asian folk medicine. Apop-
tosis is programmed active cell death. A number of anti-
cancer drugs have been screened and selected based on
their abilities to initiate the physiological events that
culminates in cell death [7]. We observed the presence
of membrane blebs, and chromatin condensation in the
fluorescent micrographs of clausenidin treated HT-29
cells which represents features of incipient apoptosis
[27]. Similarly, the ultrastructural micrograph revealed
morphological aberrations within the organelles in HT-
29 cells associated with apoptosis. The apoptotic features
observed includes appearance of lipid droplets (as a re-
sult of cell membrane damage), condensation of chro-
matin and nuclear fragmentation which further
corroborated apoptosis in the clausenidin treated HT-29
cells.
DNA fragmentation and loss of mitochondrial mem-
brane integrity precedes apoptosis [8]. Clausenidin
caused a nucleosomal DNA cleavage in HT-29 cells
which led to the generation of DNA fragments as shown
earlier in the gel image result. The generation of DNA
fragments increased as the treatment time progressed
suggesting the ability of clausenidin to sustain apoptosis
in HT-29 cells. As a proof of the apoptosis-inducing
Fig. 10 Caspase activities in clausenidin-treated HT-29 cells. Analyses in triplicates. (*Significant difference between means at p < 0.05)
Fig. 11 Caspase, Cyt c, Apaf 1, Bax and Bcl2 gene expressions in clausenidin-treated HT-29 cells. Analyses in triplicates. (*Significant difference
between means at p < 0.05)
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effect of clausenidin, we observed a loss of MMP in the
HT-29 cells which is a prerequisite for apoptosis to
occur via the mitochondrial pathway. Also, apoptosis in-
duced by some chemotherapeutic agents is controlled by
the ratio of bax:bcl 2 expressions in the mitochondria
[28]. Increased expression of Bax is known to stimulate
a collapse of MMP which terminates in apoptosis [29].
Our gene expression study result shows a significant in-
crease (p < 0.05) in the bax level which could have trig-
gered the MMP collapse in clausenidin treated HT-29
cells observed earlier. In addition, a significant increase
(p < 0.05) in cytochrome c and Apaf-1 genes expression
were observed after treatment with clausenidin. Mito-
chondrial release of cytochrome c into the cytoplasm en-
ables it to interact with dATP and Apaf-1 to form the
apoptosome complex and subsequent activation of cas-
pases [26]. The mitochondria has been described as a
major component of the intrinsic pathway because of its
ability to activate the apoptosis program directly. There-
fore, we suspect that the increased levels of the apop-
totic genes as observed in this study could have been
triggered by clausenidin induced mitochondrial signal-
ing. In a recent study with dentatin isolated also from C.
excavata, it was observed that apoptosis occurred via
mitochondrial pathway signaling in the dentatin-treated
MCF-7 breast cancer cells [21].
Moreover, the expressions of caspases 3 and 9 proteins
increased significantly (p < 0.05) after treating the HT-29
cells with clausenidin. Caspase 9 is a key regulator of
mitochondrial apoptosis, because it functions as a gate-
keeper of the intrinsic pathway [11]. So therefore, an in-
crease in the expression of caspase 9 protein and gene as
observed in this study strongly suggests the involvement
of the intrinsic pathway (mitochondrial pathway) in the
induction of apoptosis in clausenidin-treated HT-29
cells. Impaired functions of the caspase 9 promoter or
caspase 9 gene which leads to low activity of caspase 9
has been implicated as a cause of various cancers such
as colon cancer [30–33]. We observed that clausenidin
treatment significantly increased (p < 0.05) the expres-
sion of caspase 9 gene by over two (2) folds. It is no sur-
prise that the caspase 3 expression also increased
significantly since it depends on caspase 9 for activation
[11]. Caspase 3 executes apoptosis via selective destruc-
tion of subcellular structures, organelles or even the gen-
ome [11]. Our earlier results of TEM and DNA
fragmentation analysis confirms this process of subcellu-
lar destruction. An increased expression of caspases 3
and 9 have also been reported in breast cancer cells
treated with dentatin isolated from C. excavata [21].
One of the mechanisms by which anticancer agents in-
duce apoptosis is through the creation of oxidative imbal-
ance, which is a consequence of increased intracellular
ROS production beyond the capacity of antioxidant
defense system [34]. Previous studies have shown that
there is a relationship between the mitochondrial derived
ROS and the activation of caspases [35, 36]. The increased
production of ROS in the present study could have trig-
gered the clausenidin induced apoptosis in HT-29 cells as
shown by our TEM micrographs. ROS has been reported
to cause DNA strand cleavage as well as cell membrane
injury [34] which we observed in the present study.
However, insensitivity to growth inhibitory signals has
been proposed as one of the hallmarks of cancer survival
strategy [11]. This leads to an inability to regulate the
cell cycle which culminates in the development of cancer
[37]. The cell cycle result shows that clausenidin induces
a G0/G1 arrest in HT-29 cells. This finding could sug-
gest another pathway through which clausenidin elicits
signals that inhibits/controls the growth of tumor cells.
Another vital observation in the cell cycle assay is the
significant increase in the fractionated DNA of the clau-
senidin treated cells as represented by the sub G0/G1
fraction. This important finding and other results pre-
sented in this study lends credence to the occurrence of
apoptosis in the clausenidin treated HT-29 cells.
Conclusion
Apoptosis was induced successfully in colon cancer cells
using clausenidin isolated from C. excavata. The
clausenidin-stimulated apoptosis occurred via increased
expressions of caspases 3 and 9. In addition, the current
study justifies claims of anti-tumor properties of
Clausena excavata Burm. f. in the traditional treatment
of malignant cancers.
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